Skip to main content
Home > The Daily Extra > Company News

Chronological Index of : Company News

 Current Issue
  • COMPANY NEWS: J&J launches JLABS incubator in Toronto

    Johnson & Johnson (NYSE:JNJ) launched a JLABS incubator in Toronto, its first incubator outside the U.S. Based in the MaRS Discovery District, the incubator has relationships with six hospitals, including the University…

    Published on 5/11/2016
  • COMPANY NEWS: ChemoCentryx, Vifor in deal for rare renal disease candidate

    ChemoCentryx Inc. (NASDAQ:CCXI) rose $0.89 (42%) to $2.99 on Tuesday after it granted the Vifor Pharma Ltd. subsidiary of Galenica Ltd. (SIX:GALN) exclusive rights to commercialize CCX168 in Europe, Canada, Mexico, …

    Published on 5/10/2016
  • COMPANY NEWS: Indian Patent Office overturns Sovaldi ruling

    The Indian Patent Office of New Delhi granted Gilead Sciences Inc. (NASDAQ:GILD) a patent covering active metabolites of HCV drug Sovaldi sofosbuvir, reversing an earlier ruling (see BioCentury Extra, Jan. 15, 2015).In …

    Published on 5/10/2016
  • COMPANY NEWS: JHL opens biologics manufacturing site in China

    JHL Biotech Inc. (TPex-E:6540) said it opened a biomanufacturing facility in Wuhan, giving it the largest single-use cell culture capacity in Asia.The new manufacturing facility is designed to produce biosimilars and …

    Published on 5/10/2016
  • COMPANY NEWS: Management tracks

    Drug discovery company Confo Therapeutics N.V. (Brussels, Belgium) hired Christel Menet as CSO. She was director of chemistry at Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG).Ophthalmic company Opko Health Inc. (NYSE:OPK;…

    Published on 5/10/2016
  • COMPANY NEWS: Incyte buying Ariad's European operations, Iclusig rights

    Incyte Corp. (NASDAQ:INCY) will acquire the European operations of Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), including exclusive rights to leukemia drug Iclusig ponatinib in the EU and 22 other countries including …

    Published on 5/9/2016
  • COMPANY NEWS: Management tracks

    Metabolic company Arena Pharmaceuticals Inc. (NASDQ:ARNA) named Amit Munshi CEO and interim principal financial officer. He was president and CEO at Epirus Biopharmaceuticals Inc. (NASDAQ:EPRS). Epirus named Scott …

    Published on 5/9/2016
  • COMPANY NEWS: Medicines Co. selling some CV assets to Chiesi

    The Medicines Co. (NASDAQ:MDCO) is selling its non-core cardiovascular assets to Chiesi Farmaceutici S.p.A. (Parma, Italy). The deal includes Cleviprex clevidipine, Kengreal cangrelor and the company's rights to ready …

    Published on 5/9/2016
  • COMPANY NEWS: PureTech launches Vor BioPharma

    PureTech Health plc (LSE:PRTC) launched Vor BioPharma Inc., an immuno-oncology company focused on chimeric antigen receptor (CAR) T cell therapies. PureTech said the newco licensed IP from the laboratory of Siddhartha …

    Published on 5/9/2016
  • COMPANY NEWS: KemPharm hammered after FDA panel

    KemPharm Inc. (NASDAQ:KMPH) sank $8.76 (56%) to $6.91 on Friday, a day after FDA advisory committees voted against labeling analgesic Apadaz benzhydrocodone/acetaminophen as an abuse deterrent product. The committees …

    Published on 5/6/2016
  • COMPANY NEWS: MD Anderson becomes Hengrui's latest academic partner

    Jiangsu Hengrui Medicine Co. Ltd. (Shanghai:600276) and the University of Texas MD Anderson Cancer Center began a three-year translational research collaboration to develop combination immunotherapies for cancer. Last …

    Published on 5/6/2016
  • COMPANY NEWS: Newco Vitaeris licenses Alder's clazakizumab

    Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) granted newco Vitaeris Inc. (Vancouver, B.C.) exclusive, worldwide rights to anti-IL-6 mAb clazakizumab (formerly ALD518). Alder helped co-found Vitaeris to house clazakizumab…

    Published on 5/6/2016
  • COMPANY NEWS: Clovis dropping rociletinib, focusing on rucaparib

    Clovis Oncology Inc. (NASDAQ:CLVS) said late Thursday that it expects FDA to issue a complete response letter for an NDA for rociletinib (CO-1686). The company intends to focus resources instead on its next most-…

    Published on 5/5/2016
  • COMPANY NEWS: Medivation holds firm as Sanofi raises takeout pressure

    Medivation Inc. (NASDAQ:MDVN) again rejected an acquisition offer from Sanofi (Euronext:SAN; NYSE:SNY) as CEO David Hung insisted Thursday that the company's existing business plan would create more shareholder value …

    Published on 5/5/2016
  • COMPANY NEWS: Merck's Frazier discusses deal appetite

    Merck & Co. Inc. (NYSE:MRK) President and CEO Kenneth Frazier said the pharma is actively searching for licensing or bolt-on deals, and would consider a deal larger than its $8.4 billion takeout of Cubist …

    Published on 5/5/2016
  • COMPANY NEWS: NICE now backs both Repatha and Praluent

    The U.K.'s NICE issued final appraisal determinations (FADs) recommending the use of PCSK9 inhibitors Praluent alirocumab and Repatha evolocumab. The committee backed both drugs for primary non-familial …

    Published on 5/5/2016
  • COMPANY NEWS: Panel backs KemPharm analgesic, doubts abuse deterrence

    FDA's Anesthetic and Analgesic Drug Products and Risk Management Advisory Committees voted 16-4 that the agency should approve Apadaz benzhydrocodone/acetaminophen (KP201/APAP) from KemPharm Inc. (NASDAQ:KMPH) for the …

    Published on 5/5/2016
  • COMPANY NEWS: Regeneron raises Eylea guidance

    Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) gained $17.09 to $377.73 on Thursday after it reported earnings and raised 2016 guidance for sales of its ophthalmic drug Eylea aflibercept. The company now expects 20-25% …

    Published on 5/5/2016
  • COMPANY NEWS: Wave, Pfizer begin metabolic disease collaboration

    Wave Life Sciences Ltd. (NASDAQ:WVE) and Pfizer Inc. (NYSE:PFE) partnered to design and develop stereopure nucleic acid therapeutics for metabolic diseases. The partners will investigate therapies for five genetically …

    Published on 5/5/2016
  • COMPANY NEWS: Management tracks

    Gene therapy company uniQure N.V. (NASDAQ:QURE) named Paul Firuta chief commercial officer. He was chief commercial officer at BioBlast Pharma Ltd. (NASDAQ:ORPN).Metabolic company Orexigen Therapeutics Inc. (NASDAQ:OREX…

    Published on 5/4/2016
  • COMPANY NEWS: Priority Review for Lilly's olaratumab

    Eli Lilly and Co. (NYSE:LLY) said FDA accepted and granted Priority Review to a BLA for olaratumab (LY3012207) in combination with doxorubicin to treat advanced soft tissue sarcoma (STS) that cannot be treated with …

    Published on 5/4/2016
  • COMPANY NEWS: Alnylam tumbles on ALN-CC5 update

    Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) fell $7.98 (12%) to $60.81 on Tuesday after reporting that it will narrow its development program for paroxysmal nocturnal hemoglobinuria (PNH) therapy ALN-CC5 to target poor …

    Published on 5/3/2016
  • COMPANY NEWS: Quintiles, IMS Health merging

    CRO Quintiles Transnational Holdings Inc. (NYSE:Q) and healthcare data and IT company IMS Health Holdings Inc. (NYSE:IMS) are merging in an all-stock deal. The parties expect the deal to close next half.The companies …

    Published on 5/3/2016
  • COMPANY NEWS: Koppel to leave Biogen

    Biogen Inc. (NASDAQ:BIIB) said EVP of Strategy and Business Development Adam Koppel will leave the company on June 2. He had led the biotech's business development activities since EVP of Corporate Development Steven …

    Published on 5/2/2016
  • COMPANY NEWS: AZ cutting costs, boosting oncology investment

    In its 1Q16 earnings report Friday, AstraZeneca plc (NYSE:AZN; LSE:AZN) said it would reduce core SG&A expenses to support continued investment in oncology. AZ estimated $1.1 billion in savings from unspecified cuts, …

    Published on 4/29/2016

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993